Riskpilot← Back to searchSign inGet full accessSprint Bioscience AB
ABActiveOrg 5567897557Hälsovägen 7Research and experimental development on natural sciences and engineering · NACE 7210Est. 200937 employees
Revenue 2024
SEK 65,6M
+30% vs 2023
EBITDA margin
-28.5%
-4601% vs 2023
Equity ratio
22.0%
Financial strength
Net profit 2024
SEK -18,3M
-4073% vs 2023
| Revenue | SEK 65,6M | +30% |
| EBITDA | SEK -18,7M | -4601% |
| Net profit | SEK -18,3M | -4073% |
| Total assets | SEK 42,1M | -33% |
| Equity | SEK 9,3M | -67% |
| Employees | 37 | — |
Legal name
Sprint Bioscience AB
Org number
5567897557
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
28 september 2009
Share capital
SEK 6 982 000
Employees
37 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva utveckling av läkemedel och därmed förenlig verksamhet.
Address
Hälsovägen 7
Phone
+4684114455
Email
info@sprintbioscience.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 17 936 | 33 541 | 16 885 | 35 114 | 83 | 50 485 | 65 641 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −15 149 | 7 902 | −10 104 | −21 355 | −19 509 | −37 151 | −25 038 | −60 122 | −398 | −18 710 |
| Depreciation & amort. | −208 | −3 336 | −564 | −704 | −731 | −697 | −590 | −618 | −447 | −958 |
| EBIT | −15 357 | 4 566 | −10 668 | −22 059 | −20 240 | −37 848 | −25 628 | −60 740 | −845 | −19 668 |
| Net financials | −144 | −26 | 5 | −156 | −1 296 | −4 944 | 545 | 571 | 407 | 1 391 |
| Profit before tax | −15 500 | 4 541 | −10 663 | −22 216 | −21 536 | −42 792 | −25 083 | −60 170 | −438 | −18 277 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −15 500 | 4 541 | −10 663 | −22 216 | −21 536 | −42 792 | −25 083 | −60 170 | −438 | −18 277 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 30 633 | 49 522 | 35 485 | 59 290 | 19 244 | 33 399 | 79 137 | 37 422 | 62 377 | 42 055 |
| Equity | 4 820 | 28 495 | 28 089 | 37 243 | 11 017 | 9 144 | 70 454 | 28 188 | 27 774 | 9 272 |
| Long-term debt | 769 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 25 044 | 21 027 | 7 396 | 22 046 | 8 227 | 24 255 | 8 683 | 9 234 | 34 603 | 32 783 |
| Total debt | 25 813 | 21 027 | 7 396 | 22 046 | 8 227 | 24 255 | 8 683 | 9 234 | 34 603 | 32 783 |
EBITDA margin
-28.5%
This company
15.8%
Market median
-280% vs market
20152024
Equity ratio
22.0%
This company
38.2%
Market median
-42% vs market
20152024
Return on equity
-197.1%
This company
18.4%
Market median
-1171% vs market
20152024
Net profit margin
-27.8%
This company
8.1%
Market median
-443% vs market
20152024
Asset turnover
1.56×
This company
1.12×
Market median
+39% vs market
20152024
Debt / equity
3.54×
This company
0.62×
Market median
-471% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EM Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
JE Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
JM Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
KL Chief Auditor | Chief Auditor | 2020 | — | — |
MP Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
JE Chief Auditor | Chief Auditor | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Sprint Bioscience AB 
Fragment Finans ABBoard members of Sprint Bioscience AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Myung-Jin Kinnman | Chief Executive Officer | 0 companies |
| Johan Emil Emilsson | Chief Executive Officer | 0 companies |
| Jessica Marie Martinsson | Chief Executive Officer | 0 companies |
| Karl Leonard Daun | Chief Auditor | 0 companies |
| Mathias Per Skalmstad | Chief Executive Officer | 0 companies |
| Johan Erik Niclas Bergenmo | Chief Auditor | 0 companies |
| Svein Arild Mathisen | Board of Directors | 0 companies |
| Björn Magnus Sjöstrand | Chairman | 0 companies |
| Lars Erik Björk | Board of Directors | 0 companies |
| Charlotte Hilda Helena Leife | Board of Directors | 0 companies |
| Nils Rune Nordlander | Board of Directors | 0 companies |
| Per Fredrik Lehmann | Board of Directors | 0 companies |
| Karen Elisabeth From | Board of Directors | 0 companies |
| Karin Charlotta Liljebris | Board of Directors | 0 companies |
| Jan-Erik Nyström | Board of Directors | 0 companies |